(37), MerTK inhibition by small molecule tyrosine kinase, MRX2843, could change the leukemia microenvironment from tumor-permissive toward immune responsiveness to leukemia, as well as enhance the AML clearance mediated by immune. The gene discussed is MERTK; the disease is leukemia.